Dr. Robin L. Smith, currently Chairman of the Board of Directors of Caladrius Biosciences (formerly NeoStem, NASDAQ: CLBS), was elevated to Executive Chairman of NeoStem in January 2015 after having previously served as Chairman and Chief Executive Officer of the company from 2006 to 2015. Additionally, she serves as Chairman of the Board of Trustees and President of the Stem for Life foundation, a non-profit entity with the goal of raising awareness about adult stem cell therapies and their therapeutic promise, as well as supporting the advancement of research of adult stem cells.
Dr. Smith has positioned Caladrius as a leader in the emerging stem cell industry, built on a successful business model that combines a proprietary therapeutic development business and a successful contract development and manufacturing organization (CDMO) which provides services to others in the regenerative medicine industry. Under her leadership, Caladrius has successfully completed six acquisitions, one divestiture and has raised more than 200 million dollars for research and development, expansion of business units, and strategic transactions. Caladrius ranked number one (for the second year in a row) in the Tri-State region and number 11 nationally on Deloitte’s 2013 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. In 2010, Caladrius was awarded the New Economy “Best Stem Cell Company” award.